HONG KONG and LOS ANGELES, April 26, 2011 /PRNewswire-Asia/ -- Artificial Life, Inc., (OTC BB: ALIFE), a leading provider of award-winning mobile technology and applications, announced today the launch of Opus-M Health: Neurodermatitis (short form: Opus-M Health: Nd), their second major mobile telemedicine health solution for iPhone/iPod touch which is now available on the Apple App Store.
Opus-M Health: Nd (previously known as NeuroDerMo) is a healthcare app which serves as an electronic diary and monitoring tool for patients suffering from lichen simplex chronicus (neurodermatitis), a serious skin disorder characterized by chronic itching and scratching. According to research, it is suffered by six percent of the world's population and is becoming increasingly common around the globe*.
Features of Opus-M Health: Nd include:
- Simple and easy-to-use data input for photo & text entries
- A slideshow function to show the healing process over time
- An interactive graph to track and visualize measurements of areas of the skin that are being monitored for neurodermatitis
- PDF summaries of data that can be exported to patients and caregivers medical records via iTunes sharing
- Health tips on skin care to minimize the effects of neurodermatitis
Opus-M Health: Nd is a member of Artificial Life (ALIFE)'s Opus-M Health platform, which already features GluCoMo, a diabetes monitoring app, as well as an upcoming application that will be used for the management of HIV/AIDS, Opus-M Health: HIV/AIDS. The Opus-M Health platform will expand to feature other healthcare apps developed by the Company.
Opus-M Health: Nd is now available for download for free at: http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewSoftware?id=432814171&mt=8
In the future, users will have the option to obtain more advanced functions and features in the app with a subscription fee. You can find out more about this title and other apps and games by Artificial Life at www.botme.com.
"We are excited that our Opus-M Health family is growing and look forward to supporting many other users in their healthcare management in the future," said Eberhard Schoneburg, CEO of Artificial Life Inc.
*Source: Schafer, Gunther N. Psoriasis - Neurodermatitis, Atopic Eczema Answers to Everyday Questions from A - Z. [Bad Sackingen]: G. N. Schafer, 2006. Print.
iPhone and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.
About Artificial Life, Inc.
Artificial Life, Inc. has been a pioneer in artificial intelligence and mobile technology since its inception in Boston in 1994. We are a public US corporation (OTC BB: ALIFE) with listing on the Frankfurt Stock Exchange (Frankfurt: AIF.F; Xetra: AIF.DE) and headquarters and production center in Hong Kong. We have additional offices in Berlin, Germany (EMEA headquarters), Tokyo, Japan, and Santa Monica, USA. Currently our main business areas are: high quality (3D) interactive (massively multiplayer) mobile games, mobile participation television, mobile business applications, our powerful mobile commerce technology platform OPUS-M™ and our green IT solutions provided by Green Cortex, Inc. We have won many industry awards for our outstanding technology and products.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding our future results of operations, financial condition and business prospects. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the negative of these terms or other comparable terminology. Although such statements are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on them. These statements involve risks and uncertainties, and actual market trends or our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied in these forward looking statements for a variety of reasons. Potential risks and uncertainties include, but are not limited to, our ability to obtain additional funding to operate and grow our business; the unproven potential of our mobile gaming business model; changing consumer preferences and uncertainty of market acceptance of our products; timely adoption and availability of 3G mobile technology; market acceptance for use of mobile handheld devices to play the interactive games; unpredictable mobile game development schedules; our reliance on a relatively small number of brands; our ability to license brands from others; our dependence upon resellers and telecommunication carriers and operators to distribute our products; our ability to successfully develop, introduce, and sell new or enhanced products in a timely manner; and the timing of new product announcements or introductions by us or by our competitors. For additional discussion of these risks and uncertainties and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB filed on March 16, 2010. We assume no obligation to update any forward-looking statements, which apply only as of the date of this press release.
For more information on ARTIFICIAL LIFE, INC., please contact:
Artificial Life IR and PR Contact:
Tel: (+852) 3102 2800
SOURCE Artificial Life, Inc.